McKesson and CD&R strike $5.8bn deal to buy infusion services provider
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"McKesson and CD&R strike $5.8bn deal to buy infusion services provider" is generating significant coverage in the Business category, with 1 articles from 1 distinct sources tracked by PULSE so far.
Outlets currently covering the story include Financial Times. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 4d ago.
Quick answers
Why is "McKesson and CD&R strike $5.8bn deal to buy infusion services provider" trending?
Because 1 independent news sources published 1 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (1)
- McKesson and CD&R strike $5.8bn deal to buy infusion services provider Financial Times · 6d ago
Topics
Related trends
McKesson, CD&R near $5 billion-plus deal to buy Option Care, FT reports
Option Care Health stock skyrocketed following a $5.8 billion buyout agreement with McKesson and CD&R.
Hackers claim millions of patient records stolen during data breach at healthcare giant McKesson
14 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
McKesson strikes $2.25 billion Precision Medicine deal in clinical research bets
McKesson has entered a definitive agreement to acquire Precision Medicine Group, LLC for $2.25 billion to expand its clinical research capabilities.